In mid-2021, Alentis closed the Series B financing round, raising USD 67 million. Series B was led by Morningside Venture Investments and Jeito Capital and the Series A investors to accelerate its lead programs for fibrosis and fibrosis-driven cancers into clinical development and to expand the potential of targeting CLDN1 in other fibrotic diseases.

Alentis was founded in 2019 with a CHF 12.5 million Series A financing co-led by Swiss venture capital firms BioMedPartners and BB Pureos Bioventures, with additional investments from Bpifrance, Schroder Adveq, and the German High-Tech Gründerfonds.